RU2005127584A - Новые замещенные производные 2,3-бензодиазепина - Google Patents
Новые замещенные производные 2,3-бензодиазепина Download PDFInfo
- Publication number
- RU2005127584A RU2005127584A RU2005127584/04A RU2005127584A RU2005127584A RU 2005127584 A RU2005127584 A RU 2005127584A RU 2005127584/04 A RU2005127584/04 A RU 2005127584/04A RU 2005127584 A RU2005127584 A RU 2005127584A RU 2005127584 A RU2005127584 A RU 2005127584A
- Authority
- RU
- Russia
- Prior art keywords
- methyl
- group
- benzodiazepine
- dioxolo
- dihydro
- Prior art date
Links
- RPBDCDQMCRHNLM-UHFFFAOYSA-N C1=NNC=C2C=CC=CC2=C1 Chemical class C1=NNC=C2C=CC=CC2=C1 RPBDCDQMCRHNLM-UHFFFAOYSA-N 0.000 title claims 6
- 150000001875 compounds Chemical class 0.000 claims 29
- 150000003839 salts Chemical class 0.000 claims 11
- 238000000034 method Methods 0.000 claims 10
- 239000002253 acid Substances 0.000 claims 9
- -1 cyanomethyl group Chemical group 0.000 claims 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 4
- 230000001154 acute effect Effects 0.000 claims 4
- 125000003277 amino group Chemical group 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 3
- 230000004064 dysfunction Effects 0.000 claims 3
- 229930195712 glutamate Natural products 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- HCOJNYUPUOBYDH-GFCCVEGCSA-N 2-methyl-4-[(8r)-8-methyl-7-(1,3,4-thiadiazol-2-yl)-8,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl]aniline Chemical compound C([C@H]1C)C2=CC=3OCOC=3C=C2C(C=2C=C(C)C(N)=CC=2)=NN1C1=NN=CS1 HCOJNYUPUOBYDH-GFCCVEGCSA-N 0.000 claims 2
- DZISRJWEOMPAIL-ISZGNANSSA-N 2-methyl-4-[(8r)-8-methyl-7-[5-[(e)-prop-1-enyl]-1,3,4-thiadiazol-2-yl]-8,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl]aniline Chemical compound S1C(/C=C/C)=NN=C1N1[C@H](C)CC2=CC(OCO3)=C3C=C2C(C=2C=C(C)C(N)=CC=2)=N1 DZISRJWEOMPAIL-ISZGNANSSA-N 0.000 claims 2
- OTLOBZLSZJVQQA-CYBMUJFWSA-N 4-[(8r)-7-(5-ethyl-1,3,4-thiadiazol-2-yl)-8-methyl-8,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl]-2-methylaniline Chemical compound S1C(CC)=NN=C1N1[C@H](C)CC2=CC(OCO3)=C3C=C2C(C=2C=C(C)C(N)=CC=2)=N1 OTLOBZLSZJVQQA-CYBMUJFWSA-N 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 210000002345 respiratory system Anatomy 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 1
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical compound C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 claims 1
- OGVWWGVZVJUPHF-UHFFFAOYSA-N 1,2,4-thiadiazol-3-one Chemical compound O=C1N=CSN1 OGVWWGVZVJUPHF-UHFFFAOYSA-N 0.000 claims 1
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical compound C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 claims 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 claims 1
- 125000004521 1,3,4-thiadiazol-2-yl group Chemical group S1C(=NN=C1)* 0.000 claims 1
- MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical compound C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 claims 1
- FNMGRVLXWOVONV-UHFFFAOYSA-N 1,3-thiazin-4-one Chemical compound O=C1C=CSC=N1 FNMGRVLXWOVONV-UHFFFAOYSA-N 0.000 claims 1
- CEBAFUFWRQAHJL-UHFFFAOYSA-N 1,4,2-oxathiazole Chemical compound C1ON=CS1 CEBAFUFWRQAHJL-UHFFFAOYSA-N 0.000 claims 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 claims 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 claims 1
- JWLGGEABBPDPML-LLVKDONJSA-N 2-chloro-4-[(8r)-7-[5-(methoxymethyl)-1,3,4-thiadiazol-2-yl]-8-methyl-8,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl]aniline Chemical compound S1C(COC)=NN=C1N1[C@H](C)CC2=CC(OCO3)=C3C=C2C(C=2C=C(Cl)C(N)=CC=2)=N1 JWLGGEABBPDPML-LLVKDONJSA-N 0.000 claims 1
- CPDCZSIMXFZSGX-SNVBAGLBSA-N 2-chloro-4-[(8r)-8-methyl-7-(5-methyl-1,3,4-thiadiazol-2-yl)-8,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl]aniline Chemical compound C([C@H]1C)C2=CC=3OCOC=3C=C2C(C=2C=C(Cl)C(N)=CC=2)=NN1C1=NN=C(C)S1 CPDCZSIMXFZSGX-SNVBAGLBSA-N 0.000 claims 1
- DBDUGNPURSLMPS-GFCCVEGCSA-N 2-methyl-4-[(8r)-8-methyl-7-(5-methyl-1,3,4-thiadiazol-2-yl)-8,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl]aniline Chemical compound C([C@H]1C)C2=CC=3OCOC=3C=C2C(C=2C=C(C)C(N)=CC=2)=NN1C1=NN=C(C)S1 DBDUGNPURSLMPS-GFCCVEGCSA-N 0.000 claims 1
- MONKZQOLZPOZJW-CQSZACIVSA-N 2-methyl-4-[(8r)-8-methyl-7-(5-propyl-1,3,4-thiadiazol-2-yl)-8,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl]aniline Chemical compound S1C(CCC)=NN=C1N1[C@H](C)CC2=CC(OCO3)=C3C=C2C(C=2C=C(C)C(N)=CC=2)=N1 MONKZQOLZPOZJW-CQSZACIVSA-N 0.000 claims 1
- OBQQXJNPNJYUKU-UHFFFAOYSA-N 2h-1,3,4-thiadiazol-5-one Chemical compound O=C1SCN=N1 OBQQXJNPNJYUKU-UHFFFAOYSA-N 0.000 claims 1
- CZWWCTHQXBMHDA-UHFFFAOYSA-N 3h-1,3-thiazol-2-one Chemical compound OC1=NC=CS1 CZWWCTHQXBMHDA-UHFFFAOYSA-N 0.000 claims 1
- ZMKBCJHGTFWHJI-GFCCVEGCSA-N 4-[(8r)-7-(4,5-dihydro-1,3-thiazol-2-yl)-8-methyl-8,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl]aniline Chemical compound C([C@H]1C)C2=CC=3OCOC=3C=C2C(C=2C=CC(N)=CC=2)=NN1C1=NCCS1 ZMKBCJHGTFWHJI-GFCCVEGCSA-N 0.000 claims 1
- JRXDNQCAOCOIGM-GFCCVEGCSA-N 4-[(8r)-7-(5-ethyl-1,3,4-thiadiazol-2-yl)-8-methyl-8,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl]aniline Chemical compound S1C(CC)=NN=C1N1[C@H](C)CC2=CC(OCO3)=C3C=C2C(C=2C=CC(N)=CC=2)=N1 JRXDNQCAOCOIGM-GFCCVEGCSA-N 0.000 claims 1
- LYMPRUAGULHXGA-CYBMUJFWSA-N 4-[(8r)-7-[5-(methoxymethyl)-1,3,4-thiadiazol-2-yl]-8-methyl-8,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl]-2-methylaniline Chemical compound S1C(COC)=NN=C1N1[C@H](C)CC2=CC(OCO3)=C3C=C2C(C=2C=C(C)C(N)=CC=2)=N1 LYMPRUAGULHXGA-CYBMUJFWSA-N 0.000 claims 1
- AQVHOPUVJNUMRK-LLVKDONJSA-N 4-[(8r)-8-methyl-7-(1,3,4-thiadiazol-2-yl)-8,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl]aniline Chemical compound C([C@H]1C)C2=CC=3OCOC=3C=C2C(C=2C=CC(N)=CC=2)=NN1C1=NN=CS1 AQVHOPUVJNUMRK-LLVKDONJSA-N 0.000 claims 1
- CUFZAXVDJYYCST-GFCCVEGCSA-N 4-[(8r)-8-methyl-7-(1,3-thiazol-2-yl)-8,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl]aniline Chemical compound C([C@H]1C)C2=CC=3OCOC=3C=C2C(C=2C=CC(N)=CC=2)=NN1C1=NC=CS1 CUFZAXVDJYYCST-GFCCVEGCSA-N 0.000 claims 1
- CNJBMCKQTBPYCD-LLVKDONJSA-N 4-[(8r)-8-methyl-7-(5-methyl-1,3,4-oxadiazol-2-yl)-8,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl]aniline Chemical compound C([C@H]1C)C2=CC=3OCOC=3C=C2C(C=2C=CC(N)=CC=2)=NN1C1=NN=C(C)O1 CNJBMCKQTBPYCD-LLVKDONJSA-N 0.000 claims 1
- SGQFSRKCDSMQQY-LLVKDONJSA-N 4-[(8r)-8-methyl-7-(5-methyl-1,3,4-thiadiazol-2-yl)-8,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl]aniline Chemical compound C([C@H]1C)C2=CC=3OCOC=3C=C2C(C=2C=CC(N)=CC=2)=NN1C1=NN=C(C)S1 SGQFSRKCDSMQQY-LLVKDONJSA-N 0.000 claims 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000030090 Acute Disease Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000007101 Muscle Cramp Diseases 0.000 claims 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000003556 anti-epileptic effect Effects 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 201000006517 essential tremor Diseases 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000003158 myorelaxant agent Substances 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 150000003536 tetrazoles Chemical class 0.000 claims 1
- YGNGABUJMXJPIJ-UHFFFAOYSA-N thiatriazole Chemical compound C1=NN=NS1 YGNGABUJMXJPIJ-UHFFFAOYSA-N 0.000 claims 1
- CBDKQYKMCICBOF-UHFFFAOYSA-N thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
- C07D253/10—Condensed 1,2,4-triazines; Hydrogenated condensed 1,2,4-triazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/02—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/358,053 | 2003-02-04 | ||
| US10/358,053 US6858605B2 (en) | 2003-02-04 | 2003-02-04 | Substituted 2,3-benzodiazepine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005127584A true RU2005127584A (ru) | 2006-01-27 |
Family
ID=32771128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005127584/04A RU2005127584A (ru) | 2003-02-04 | 2004-02-03 | Новые замещенные производные 2,3-бензодиазепина |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US6858605B2 (enExample) |
| EP (1) | EP1592673A4 (enExample) |
| JP (1) | JP2006516647A (enExample) |
| KR (1) | KR20050105443A (enExample) |
| CN (1) | CN1747938A (enExample) |
| AR (1) | AR043023A1 (enExample) |
| AU (1) | AU2004208825A1 (enExample) |
| BR (1) | BRPI0407247A (enExample) |
| CA (1) | CA2512616A1 (enExample) |
| HR (1) | HRP20050765A2 (enExample) |
| MX (1) | MXPA05008236A (enExample) |
| NO (1) | NO20054067L (enExample) |
| RU (1) | RU2005127584A (enExample) |
| TW (1) | TW200500347A (enExample) |
| WO (1) | WO2004069197A2 (enExample) |
| ZA (1) | ZA200505352B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4702051B2 (ja) | 2003-03-05 | 2011-06-15 | 東レ株式会社 | 芳香族高分子、フィルム、電解質膜およびセパレーター |
| AU2004282018B2 (en) * | 2003-10-15 | 2009-07-23 | Sumitomo Chemical Company, Limited | 1,2,4-thiadiazole compounds and pests controlling composition containing the same |
| EA016087B1 (ru) * | 2005-12-30 | 2012-02-28 | Эгиш Дьёдьсердьяр Ньильваношан Мюкёдё Ресвеньтаршашаг | Оптические изомеры дигидро-2,3-бензодиазепинов и их стереоселективный синтез |
| RU2314829C1 (ru) * | 2006-03-21 | 2008-01-20 | Войсковая Часть 41598 | Композиция для терапии судорожного синдрома |
| TW200902024A (en) * | 2007-04-02 | 2009-01-16 | Teva Pharma | Novel 2,3-benzodiazepine derivatives and their use as antipsychotic agents |
| WO2014026997A1 (de) * | 2012-08-16 | 2014-02-20 | Bayer Pharma Aktiengesellschaft | 2,3-benzodiazepine |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU191698B (en) * | 1984-07-27 | 1987-03-30 | Gyogyszerkutato Intezet | Process for producing new 1-aryl-5h-2beta-benzodiazepines |
| HU219778B (hu) * | 1990-12-21 | 2001-07-30 | Gyógyszerkutató Intézet Közös Vállalat | Eljárás N-acil-2,3-benzodiazepin-származékok, savaddíciós sóik és az ezeket tartalmazó gyógyászati készítmények előállítására, valamint a vegyületek egy csoportja, és az ezeket tartalmazó gyógyászati készítmények |
| HU206719B (en) | 1990-12-21 | 1992-12-28 | Gyogyszerkutato Intezet | Process for producing 1-/4-acylamino-phenyl/-7,8-methylenedioxy-5h-2,3-benzodiazepine derivatives, acid addicional salts and pharmaceutical compositions containing them |
| HU219777B (hu) | 1993-07-02 | 2001-07-30 | Gyógyszerkutató Intézet Kft. | Optikailag aktív 1-(4-nitro-fenil)-4-metil-7,8-metiléndioxi-3,4-dihidro-5H-2,3-benzodiazepin és eljárás előállítására |
| DE4428835A1 (de) * | 1994-08-01 | 1996-02-08 | Schering Ag | Neue 3-substituierte 3H-2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel |
| TR199501071A2 (tr) | 1994-08-31 | 1996-06-21 | Lilly Co Eli | Dihidro-2,3-benzodiazepin türevlerinin üretilmesi icin stereoselektif islem. |
| DE69525342T2 (de) | 1994-08-31 | 2002-11-07 | Eli Lilly And Co., Indianapolis | Dihydro-2,3-benzodiazepinderivate |
| DE19604920A1 (de) * | 1996-02-01 | 1997-08-07 | Schering Ag | Neue 2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel |
| HU9600871D0 (en) | 1996-04-04 | 1996-05-28 | Gyogyszerkutato Intezet | New 2,3-benzodiazepine derivatives |
| UA67749C2 (uk) | 1997-08-12 | 2004-07-15 | Егіш Дьйодьсердьяр Рт. | Похідна 8-заміщеного-9н-1,3-діоксол/4,5-h//2,3/бензодіазепіну з властивостями амра/каїнатного антагоніста, спосіб одержання похідних, фармацевтична композиція (варіанти), спосіб її одержання та спосіб лікування |
| AU748801B2 (en) | 1997-08-12 | 2002-06-13 | Egis Gyogyszergyar Rt. | 1,3-dioxolo/4,5-H//2,3/benzodiazepine derivatives as ampa/kainate receptor inhibitors |
| HU227128B1 (en) | 1999-07-07 | 2010-07-28 | Egyt Gyogyszervegyeszeti Gyar | New 2,3-benzodiazepine derivatives |
-
2003
- 2003-02-04 US US10/358,053 patent/US6858605B2/en not_active Expired - Fee Related
-
2004
- 2004-02-03 AU AU2004208825A patent/AU2004208825A1/en not_active Abandoned
- 2004-02-03 ZA ZA200505352A patent/ZA200505352B/xx unknown
- 2004-02-03 BR BR0407247-2A patent/BRPI0407247A/pt not_active IP Right Cessation
- 2004-02-03 RU RU2005127584/04A patent/RU2005127584A/ru not_active Application Discontinuation
- 2004-02-03 WO PCT/US2004/003041 patent/WO2004069197A2/en not_active Ceased
- 2004-02-03 JP JP2006503283A patent/JP2006516647A/ja not_active Withdrawn
- 2004-02-03 KR KR1020057013696A patent/KR20050105443A/ko not_active Withdrawn
- 2004-02-03 US US10/771,847 patent/US20070027143A1/en not_active Abandoned
- 2004-02-03 EP EP04707792A patent/EP1592673A4/en not_active Withdrawn
- 2004-02-03 MX MXPA05008236A patent/MXPA05008236A/es not_active Application Discontinuation
- 2004-02-03 CA CA002512616A patent/CA2512616A1/en not_active Abandoned
- 2004-02-03 HR HR20050765A patent/HRP20050765A2/xx not_active Application Discontinuation
- 2004-02-03 CN CNA200480003526XA patent/CN1747938A/zh active Pending
- 2004-02-04 AR ARP040100342A patent/AR043023A1/es not_active Application Discontinuation
- 2004-02-04 TW TW093102551A patent/TW200500347A/zh unknown
-
2005
- 2005-09-01 NO NO20054067A patent/NO20054067L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1747938A (zh) | 2006-03-15 |
| WO2004069197A3 (en) | 2005-08-18 |
| TW200500347A (en) | 2005-01-01 |
| US20040152693A1 (en) | 2004-08-05 |
| JP2006516647A (ja) | 2006-07-06 |
| KR20050105443A (ko) | 2005-11-04 |
| NO20054067L (no) | 2005-10-25 |
| HRP20050765A2 (en) | 2006-10-31 |
| US20070027143A1 (en) | 2007-02-01 |
| AR043023A1 (es) | 2005-07-13 |
| BRPI0407247A (pt) | 2006-01-31 |
| EP1592673A2 (en) | 2005-11-09 |
| CA2512616A1 (en) | 2004-08-19 |
| WO2004069197A2 (en) | 2004-08-19 |
| AU2004208825A1 (en) | 2004-08-19 |
| ZA200505352B (en) | 2007-01-31 |
| EP1592673A4 (en) | 2006-10-25 |
| NO20054067D0 (no) | 2005-09-01 |
| US6858605B2 (en) | 2005-02-22 |
| MXPA05008236A (es) | 2006-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101345497B1 (ko) | 설폰아미드 유도체 | |
| ES2846154T3 (es) | Inhibidores de la proteína tirosina fosfatasa humana y métodos de uso | |
| US7589212B2 (en) | Human protein tyrosine phosphatase inhibitors and methods of use | |
| AU2007265454B2 (en) | Human protein tyrosine phosphatase inhibitors and methods of use | |
| RU2506263C2 (ru) | Производные оксазолидиновых антибиотиков | |
| JP4175113B2 (ja) | Ｅｐ１アンタゴニストを有効成分として含有するうつ病の治療剤 | |
| JP5717031B2 (ja) | 置換されたアゾール誘導体、この誘導体を含む医薬組成物、及びこれを利用したパーキンソン病の治療方法 | |
| CA2606087A1 (en) | Novel oxadiazole derivatives and their medical use | |
| JP2008516986A5 (enExample) | ||
| NZ244429A (en) | Benzoxazole and benzothiazole derivatives, preparation and pharmaceutical compositions thereof | |
| RU2009138600A (ru) | Амиды диазабициклоалканов, селективные в отношении ацетилхолинового подтипа никотиновых рецепторов | |
| US6166216A (en) | Compounds useful as neuro-protective agents | |
| AU2010319983A1 (en) | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | |
| JP2008516982A5 (enExample) | ||
| JP2001526223A (ja) | 置換複素環尿素を用いるｐ３８キナーゼの阻害 | |
| JP6661630B2 (ja) | ＲＯＲγｔのモジュレーターとしてのチアゾール | |
| NZ529107A (en) | Novel arylheteroalkylamine derivatives | |
| CA2978627A1 (en) | Srebp blockers for use in treating liver fibrosis, elevated cholesterol and insulin resistance | |
| RU2005127584A (ru) | Новые замещенные производные 2,3-бензодиазепина | |
| WO2012066330A1 (en) | Compounds useful as a2a receptor inhibitors | |
| JP2006516647A5 (enExample) | ||
| WO2002012187A1 (en) | Novel phenylheteroazetidines, useful as nitric oxide synthase inhibitors | |
| EP1263714B1 (en) | Novel phenylheteroalkylamine derivatives | |
| JPS5921624A (ja) | 医薬の方法及び組成物 | |
| RU2212237C2 (ru) | Средство для лечения нейрогенного воспаления |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20080212 |